Drug intelligence / Profile preview

slit-trap

Development stage: Preclinical
Lead developer: Sanofi
Modality: Small Molecules

Overview

Slit-trap is an experimental therapeutic compound designed to starve cancer cells by interfering with Slit signaling pathways, which are implicated in pathological angiogenesis and neovascularization. Developed by the Shanghai Institutes for Biological Sciences in collaboration with Sanofi, it functions as a trap for Slit proteins, preventing their interaction with Robo receptors to inhibit tumor vascularization. It was planned for first-in-human clinical testing in China targeting liver cancer around 2013, though no recent updates confirm progression beyond preclinical stages.

Targets

SLIT2 (Slit guidance ligand 2)

Beyond the preview

Go deeper on slit-trap.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on slit-trap.

Explore the full profile